Analyst Price Targets — OGN
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| April 27, 2026 8:27 pm | — | Piper Sandler | $14.00 | $13.18 | TheFly | Organon upgraded to Neutral from Underweight at Piper Sandler |
| April 10, 2026 3:02 pm | — | BNP Paribas | $12.00 | $8.69 | TheFly | Organon takeover offer could be $15 per share, says BNP Paribas |
| February 24, 2026 10:45 am | — | Barclays | $8.00 | $7.92 | TheFly | Organon price target raised to $8 from $7.50 at Barclays |
| December 8, 2025 9:26 pm | — | Barclays | $7.50 | $7.29 | TheFly | Organon initiated with an Underweight at Barclays |
| October 27, 2025 2:55 pm | David Amsellem | Piper Sandler | $5.00 | $7.13 | TheFly | Piper double downgrades Organon to Underweight after CEO resignation |
| May 15, 2025 10:42 am | David Amsellem | Piper Sandler | $18.00 | $8.77 | TheFly | Organon price target lowered to $18 from $24 at Piper Sandler |
| May 5, 2025 11:30 am | Terence Flynn | Morgan Stanley | $10.00 | $8.72 | TheFly | Organon price target lowered to $10 from $15 at Morgan Stanley |
| April 29, 2024 7:40 am | David Amsellem | Piper Sandler | $24.00 | $18.85 | StreetInsider | Organon & Co. (OGN) PT Raised to $24 at Piper Sandler |
| June 26, 2023 9:08 am | David Amsellem | Piper Sandler | $34.00 | $20.37 | Benzinga | Check Out 3 Health Care Stocks With Over 4% Dividend Yields From Wall Street's Most Accurate Analysts |
Latest News for OGN
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, plans to release its second quarter 2026 financial results via its regularly scheduled Form 10-Q filing with the Securities and Exchange Commission (“SEC”). The company also plans to disclose certain non-GAAP financial measures and their…
Recently, Zacks.com users have been paying close attention to Organon (OGN). This makes it worthwhile to examine what the stock has in store.
VANCOUVER, BC / ACCESS Newswire / July 10, 2026 / Orogen Royalties Inc. (TSXV:OGN)(OTCQX:OGNNF) ("Orogen" or the "Company") is pleased to announce its shares have been qualified to begin trading on the OTCQX®Best Market ("OTCQX"). Orogen has upgraded to OTCQX from the OTCQB® Venture Market.
Zacks.com users have recently been watching Organon (OGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Are TBRG, OGN, MDV Obtaining Fair Deals for their Shareholders? PR Newswire NEW YORK, June 25, 2026
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
Senate Trading Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
U.S. House Trading
House Trades Disclosures
| Name | Transaction Date | Type | Asset | Amount | Link |
|---|
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.